Ki67與HER2在乳腺癌中相對預(yù)后價(jià)值研究
發(fā)布時(shí)間：2019-05-19 11:51
【摘要】：第一部分Ki67與HER2在人乳腺癌細(xì)胞系的差異表達(dá)研究目的：研究Ki67與HER2在人乳腺癌細(xì)胞系MCF-7 和 MDA-MB-231的差異表達(dá),探討其表達(dá)情況與乳腺癌細(xì)胞侵襲轉(zhuǎn)移能力的相關(guān)性。方法：應(yīng)用qPCR、Western Blot方法檢測一對來源相同、侵襲轉(zhuǎn)移能力不同的人乳腺癌細(xì)胞系MCF-7和MDA-MB-231中Ki67與HER2的mRNA和蛋白表達(dá)量,分析其差異表達(dá)與乳腺癌細(xì)胞侵襲轉(zhuǎn)移能力的關(guān)系。結(jié)果：qPCR結(jié)果顯示,Ki67 mRNA相對含量在具有高侵襲轉(zhuǎn)移能力的MDA-MB-231細(xì)胞中約為低侵襲轉(zhuǎn)移能力的MCF-7細(xì)胞中的3.31倍,其差異具有統(tǒng)計(jì)學(xué)意義(P0.01)；HER2 mRNA相對含量在具有高侵襲轉(zhuǎn)移能力的MDA-MB-231細(xì)胞中約為低侵襲轉(zhuǎn)移能力的MCF-7細(xì)胞中的1.79倍(P0.05)；Ki67 mRNA在兩種細(xì)胞的含量差異大于HER2 mRNA在兩種細(xì)胞的含量差異(3.31 vs.1.79)。Western Blot結(jié)果顯示,Ki67與HER2蛋白在具有高侵襲轉(zhuǎn)移能力的MDA-MB-231細(xì)胞中的表達(dá)均高于在低侵襲轉(zhuǎn)移能力的MCF-7細(xì)胞中的表達(dá)與qPCR結(jié)果一致。結(jié)論：Ki67與HER2過表達(dá)與乳腺癌細(xì)胞的侵襲轉(zhuǎn)移能力有一定相關(guān)性。第二部分量子點(diǎn)標(biāo)記雙分子探針技術(shù)研究乳腺癌中Ki67與HER2協(xié)同表達(dá)的預(yù)后價(jià)值目的：研究乳腺癌組織中Ki67與HER2協(xié)同表達(dá)情況,探尋兩者在乳腺癌中的預(yù)后價(jià)值。方法：應(yīng)用量子點(diǎn)標(biāo)記雙分子探針技術(shù)同時(shí)原位標(biāo)記乳腺癌組織中Ki67和HER2,并用多光譜分析軟件定量Ki67和HER2的表達(dá),分析兩者協(xié)同表達(dá)與乳腺癌患者8年無病生存(8-Disease free survival,8-DFS)的關(guān)系。結(jié)果：Ki67在癌細(xì)胞核上表達(dá),標(biāo)記成紅色熒光,HER2在癌細(xì)胞膜上表達(dá),標(biāo)記成綠色熒光,兩者對比明顯,易于定量分析。Ki67與HER2表達(dá)量均與乳腺癌8-DFS呈負(fù)相關(guān)(P0.05)。中位8-DFS在高Ki67高HER2亞組明顯短于低Ki67高HER2亞組(11.7 vs.60.1月,P0.05)；在高Ki67低HER2亞組短于低Ki67低HER2亞組(16.4vs.96.0月,P0.01)；在高Ki67高HER2亞組明顯短于低Ki67低HER2亞組(11.7vs.96.0月,P0.01)；在高Ki67低HER2亞組與高Ki67高HER2亞組的差異無統(tǒng)計(jì)學(xué)意義(11.7vs.16.4月,P=0.586)。多因素分析顯示,兩者影響預(yù)后的權(quán)重不同,Ki67影響預(yù)后的風(fēng)險(xiǎn)比(Hazard ratio, HR)大約是HER2的3倍(HR 4.493 vs.1.481).結(jié)論：量子點(diǎn)標(biāo)記探針技術(shù)有助于定量分析HER2和Ki67在乳腺癌中的協(xié)同表達(dá),Ki67對乳腺癌預(yù)后不良的影響權(quán)重可能高于HER2。
[Abstract]:Part 1 differential expression of Ki67 and HER2 in human breast cancer cell line objective: to study the differential expression of Ki67 and HER2 in human breast cancer cell line MCF-7 and MDA-MB-231, and to explore the correlation between the expression of Ki67 and MDA-MB-231 and the ability of invasion and metastasis of breast cancer cell line. Methods: qPCR,Western Blot was used to detect the mRNA and protein expression of Ki67 and HER2 in a pair of human breast cancer cell lines MCF-7 and MDA-MB-231 with the same origin and different ability of invasion and metastasis. To analyze the relationship between the differential expression of breast cancer cells and the ability of invasion and metastasis of breast cancer cells. Results: the results of qPCR showed that the relative content of Ki67 mRNA in MDA-MB-231 cells with high invasion and metastasis ability was about 3.31 times higher than that in MCF-7 cells with low invasion and metastasis ability, and the difference was statistically significant (P 0.01). The relative content of HER2 mRNA in MDA-MB-231 cells with high invasion and metastasis ability was about 1.79 times higher than that in MCF-7 cells with low invasion and metastasis ability (P 0.05). The difference of Ki67 mRNA content between the two kinds of cells was greater than that of HER2 mRNA in the two kinds of cells (3.31 vs.1.79). Western Blot results showed that, The expression of Ki67 and HER2 protein in MDA-MB-231 cells with high invasion and metastasis ability was higher than that in MCF-7 cells with low invasion and metastasis ability, which was consistent with qPCR results. Conclusion: the overexpression of Ki67 and HER2 is related to the invasion and metastasis of breast cancer cells. The second part is to study the prognostic value of co-expression of Ki67 and HER2 in breast cancer by quantum dot labeling bimolecule probe. Objective: to study the co-expression of Ki67 and HER2 in breast cancer and to explore their prognostic value in breast cancer. Methods: quantum dot labeling bilayer probe technique was used to label Ki67 and HER2, in situ at the same time, and the expression of Ki67 and HER2 was quantified by multi-spectral analysis software. To analyze the relationship between the co-expression of the two and the disease-free survival (8-Disease free survival,8-DFS) of breast cancer patients for 8 years. Results: Ki67 was expressed in the nucleus of cancer, marked with red fluorescence, and HER2 was expressed on the cell membrane of cancer, marked with green fluorescence. Ki67 and HER2 expression were negatively correlated with 8-DFS in breast cancer (P 0.05). The expression of Ki67 and Ki67 was negatively correlated with the expression of Ki67 and Ki67 in breast cancer. The median 8-DFS in high Ki67 and high HER2 subgroup was significantly shorter than that in low Ki67 and high HER2 subgroup (11.7 vs.60.1 month, P 0.05), and in high Ki67 and low HER2 subgroup was shorter than that in low Ki67 and low HER2 subgroup (16.4vs.96.0 month, P 0.01). In high Ki67 and high HER2 subgroup, it was significantly shorter than that in low Ki67 and low HER2 subgroup (11.7vs.96.0 month, P 0.01), but there was no significant difference between high Ki67 and low HER2 subgroup and high Ki67 and high HER2 subgroup (11.7vs.16.4 month, P 鈮，
本文編號(hào)：2480703
[Abstract]:Part 1 differential expression of Ki67 and HER2 in human breast cancer cell line objective: to study the differential expression of Ki67 and HER2 in human breast cancer cell line MCF-7 and MDA-MB-231, and to explore the correlation between the expression of Ki67 and MDA-MB-231 and the ability of invasion and metastasis of breast cancer cell line. Methods: qPCR,Western Blot was used to detect the mRNA and protein expression of Ki67 and HER2 in a pair of human breast cancer cell lines MCF-7 and MDA-MB-231 with the same origin and different ability of invasion and metastasis. To analyze the relationship between the differential expression of breast cancer cells and the ability of invasion and metastasis of breast cancer cells. Results: the results of qPCR showed that the relative content of Ki67 mRNA in MDA-MB-231 cells with high invasion and metastasis ability was about 3.31 times higher than that in MCF-7 cells with low invasion and metastasis ability, and the difference was statistically significant (P 0.01). The relative content of HER2 mRNA in MDA-MB-231 cells with high invasion and metastasis ability was about 1.79 times higher than that in MCF-7 cells with low invasion and metastasis ability (P 0.05). The difference of Ki67 mRNA content between the two kinds of cells was greater than that of HER2 mRNA in the two kinds of cells (3.31 vs.1.79). Western Blot results showed that, The expression of Ki67 and HER2 protein in MDA-MB-231 cells with high invasion and metastasis ability was higher than that in MCF-7 cells with low invasion and metastasis ability, which was consistent with qPCR results. Conclusion: the overexpression of Ki67 and HER2 is related to the invasion and metastasis of breast cancer cells. The second part is to study the prognostic value of co-expression of Ki67 and HER2 in breast cancer by quantum dot labeling bimolecule probe. Objective: to study the co-expression of Ki67 and HER2 in breast cancer and to explore their prognostic value in breast cancer. Methods: quantum dot labeling bilayer probe technique was used to label Ki67 and HER2, in situ at the same time, and the expression of Ki67 and HER2 was quantified by multi-spectral analysis software. To analyze the relationship between the co-expression of the two and the disease-free survival (8-Disease free survival,8-DFS) of breast cancer patients for 8 years. Results: Ki67 was expressed in the nucleus of cancer, marked with red fluorescence, and HER2 was expressed on the cell membrane of cancer, marked with green fluorescence. Ki67 and HER2 expression were negatively correlated with 8-DFS in breast cancer (P 0.05). The expression of Ki67 and Ki67 was negatively correlated with the expression of Ki67 and Ki67 in breast cancer. The median 8-DFS in high Ki67 and high HER2 subgroup was significantly shorter than that in low Ki67 and high HER2 subgroup (11.7 vs.60.1 month, P 0.05), and in high Ki67 and low HER2 subgroup was shorter than that in low Ki67 and low HER2 subgroup (16.4vs.96.0 month, P 0.01). In high Ki67 and high HER2 subgroup, it was significantly shorter than that in low Ki67 and low HER2 subgroup (11.7vs.96.0 month, P 0.01), but there was no significant difference between high Ki67 and low HER2 subgroup and high Ki67 and high HER2 subgroup (11.7vs.16.4 month, P 鈮，
本文編號(hào)：2480703
本文鏈接：http://sikaile.net/yixuelunwen/zlx/2480703.html
最近更新
教材專著
